Information available to date on the use of GLP1-RAs during lactation is limited to one study which included eight women on weekly semaglutide
In contrast, Tirzepatide has been found to cause gastrointestinal side effects like vomiting along with an increased risk of hypoglycemia (low blood sugar)
ISSA Launches GLP-1 Support Course for Trainers ISSAs GLP-1 course teaches fitness coaches how to support not just the body, but the mindset and emotional shifts that come with rapid transformation As Americans turn to prescription drugs like Ozempic and Wegovy for weight loss, the International Sports Sciences Association (ISSA) is offering a new course designed to help personal trainers and health coaches better support clients taking GLP-1 medications: GLP-1 Weight Loss Support Training
Semaglutide (2.4 mg/week), approved in 2021, delivers improved weight loss compared to the earlier treatments and represents considerable progress in obesity pharmacotherapy (13)
Wightman EL, Jackson PA, Forster J, et al
Exclusive & unique formula